TY - JOUR
T1 - Imipenem/cilastatin in the treatment of obstetric and gynecologic infections
T2 - a review of worldwide experience.
AU - Sweet, Richard L
PY - 1985/7
Y1 - 1985/7
N2 - Worldwide experience with imipenem/cilastatin in the treatment of 72 patients with a variety of obstetric and gynecologic infections is reviewed. Clinical cure or improvement occurred in 97% of 72 assessable patients. The most common etiologic pathogens were Escherichia coli, group B streptococci, Neisseria gonorrhoeae, Staphylococcus epidermidis, enterococci, Bacteroides bivius, Bacteroides species, Bacteroides fragilis, and Peptostreptococcus. Of the recovered pathogens, 99.5% were susceptible to imipenem/cilastatin. Bacteriologic response was also excellent and none of the pathogens acquired resistance to imipenem. Most patients tolerated intravenous administration of imipenem/cilastatin well to moderately well.
AB - Worldwide experience with imipenem/cilastatin in the treatment of 72 patients with a variety of obstetric and gynecologic infections is reviewed. Clinical cure or improvement occurred in 97% of 72 assessable patients. The most common etiologic pathogens were Escherichia coli, group B streptococci, Neisseria gonorrhoeae, Staphylococcus epidermidis, enterococci, Bacteroides bivius, Bacteroides species, Bacteroides fragilis, and Peptostreptococcus. Of the recovered pathogens, 99.5% were susceptible to imipenem/cilastatin. Bacteriologic response was also excellent and none of the pathogens acquired resistance to imipenem. Most patients tolerated intravenous administration of imipenem/cilastatin well to moderately well.
UR - http://www.scopus.com/inward/record.url?scp=0022088235&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0022088235&partnerID=8YFLogxK
M3 - Article
C2 - 3901216
AN - SCOPUS:0022088235
VL - 7 Suppl 3
JO - Clinical Infectious Diseases
JF - Clinical Infectious Diseases
SN - 1058-4838
ER -